OSUR vs. ANIK, CERS, UTMD, ATRI, PLSE, NVRO, LUNG, SKIN, SRDX, and BVS
Should you be buying OraSure Technologies stock or one of its competitors? The main competitors of OraSure Technologies include Anika Therapeutics (ANIK), Cerus (CERS), Utah Medical Products (UTMD), Atrion (ATRI), Pulse Biosciences (PLSE), Nevro (NVRO), Pulmonx (LUNG), Beauty Health (SKIN), Surmodics (SRDX), and Bioventus (BVS). These companies are all part of the "surgical & medical instruments" industry.
OraSure Technologies (NASDAQ:OSUR) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.
OraSure Technologies has a net margin of 7.50% compared to Anika Therapeutics' net margin of -45.39%. OraSure Technologies' return on equity of 7.68% beat Anika Therapeutics' return on equity.
OraSure Technologies has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.
93.5% of OraSure Technologies shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 3.4% of OraSure Technologies shares are held by insiders. Comparatively, 5.9% of Anika Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
OraSure Technologies received 248 more outperform votes than Anika Therapeutics when rated by MarketBeat users. Likewise, 69.72% of users gave OraSure Technologies an outperform vote while only 64.38% of users gave Anika Therapeutics an outperform vote.
OraSure Technologies has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.
In the previous week, Anika Therapeutics had 3 more articles in the media than OraSure Technologies. MarketBeat recorded 5 mentions for Anika Therapeutics and 2 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of -0.30 beat Anika Therapeutics' score of -0.40 indicating that OraSure Technologies is being referred to more favorably in the media.
OraSure Technologies currently has a consensus target price of $6.63, suggesting a potential upside of 34.65%. Anika Therapeutics has a consensus target price of $29.50, suggesting a potential upside of 16.14%. Given OraSure Technologies' higher probable upside, equities analysts plainly believe OraSure Technologies is more favorable than Anika Therapeutics.
Summary
OraSure Technologies beats Anika Therapeutics on 12 of the 17 factors compared between the two stocks.
Get OraSure Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for OSUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OSUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OraSure Technologies Competitors List
Related Companies and Tools
